A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

IRB/UVA Tracking #
20169
Contact
Julio Torres
Contact Email
Contact Phone
1.434.982.4110
Phase
II
Primary purpose
Treatment
Cancer PI
Robert Dreicer
Status
OPEN TO ACCRUAL
Ages
Adult